Neue Therapieziele in der Therapie des Diabetes mellitus Typ 2 – Gewichtsreduktion als co-primäres Therapieziel

Zusammenfassung

Gemäß der Empfehlungen des aktuellen Konsensusberichts von ADA und EASD wird die Bedeutung des Gewichtsmanagements bei der Behandlung der Hyperglykämie verstärkt in den Mittelpunkt gerückt und im Behandlungsalgorithmus dem Glukosemanagement gleichgestellt. Auch wenn die Bedeutung einer Gewichtsabnahme bei der Behandlung von Patienten mit T2D seit Langem bekannt ist, gilt der aktualisierte Therapiealgorithmus als Wendepunkt in der Behandlung von Menschen mit T2D. Dieser berücksichtigt, dass mittlerweile wirksame Substanzen zur Verfügung stehen, die gleichzeitig den Blutzuckerspiegel senken und zur Gewichtsregulierung beitragen. Der neue holistische, patientenzentrierte Therapieansatz enthält darüber hinaus detailliertere Empfehlungen zu Lebensstilmaßnahmen einschließlich gesunder Ernährung, körperlicher Aktivität und Schlafqualität und -quantität.

Abstract

According to the recommendations of the current ADA and EASD consensus report, there is an increased focus on the importance of weight management in the treatment of hyperglycemia, placing it on an equal footing with glucose management in the treatment algorithm. Although the importance of weight loss in the treatment of patients with T2D has long been recognized, the updated treatment algorithm is considered a turning point in the treatment of people with T2D. The algorithm acknowledges that effective agents are now available that simultaneously lower blood glucose levels and help regulate body weight. The new holistic, patient-centered approach also includes more detailed recommendations on lifestyle measures including nutrition, physical activity and sleep quality and quantity.

Schlüsselwörter

Typ-2-Diabetes - Adipositas - co-primäres Therapieziel - Gewichtsmanagement

Key words

Type 2 diabetes - obesity - co-primary therapy goal - weight management

Publikationsverlauf

Artikel online veröffentlicht:
18. Dezember 2023

• Literatur

• 1 Davies MJ, Aroda VR, Collins BS. et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45: 2753-2786 DOI: 10.2337/DCI22-0034.
• 2 Wall JR, Pyke DA, Oakley WG. Effect of Carbohydrate Restriction in Obese Diabetics: Relationship of Control to Weight Loss. Br Med J 1973; 1: 577-578 DOI: 10.1136/BMJ.1.5853.577.
• 3 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551 DOI: 10.1016/S0140-6736(17)33102-1.
• 4 Lean MEJ, Leslie WS, Barnes AC. et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019; 7: 344-355 DOI: 10.1016/S2213-8587(19)30068-3.
• 5 Taylor R, Barnes AC, Irvine KM. et al. Diabetes remission by weight loss in „normal“ weight people with type 2 diabetes: the ReTUNE study. Im Internet: https://www.abstractsonline.com/pp8/#!/10613/presentation/308 Stand: 30.01.2023
• 6 Davies M, Færch L, Jeppesen OK. et al. Semaglutide 2 · 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021; 397: 971-984 DOI: 10.1016/S0140-6736(21)00213-0.
• 7 Wilding JPH, Batterham RL, Calanna S. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384: 989-1002 DOI: 10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDF.
• 8 Bakker W, Imbernon M, Salinas CG. et al. Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. Cell Rep 2022; 41: 111698 DOI: 10.1016/J.CELREP.2022.111698.
• 9 Imbernon M, Saponaro C, Helms HCC. et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab 2022; 34: 1054-1063.e7 DOI: 10.1016/j.cmet.2022.06.002.
• 10 Frías JP, Auerbach P, Bajaj HS. et al. Efficacy and safety of once-weekly semaglutide 2 · 0 mg versus 1 · 0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol 2021; 9: 563-574 DOI: 10.1016/S2213-8587(21)00174-1.
• 11 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844 DOI: 10.1056/NEJMOA1607141/SUPPL_FILE/NEJMOA1607141_DISCLOSURES.PDF.
• 12 Frías JP, Davies MJ, Rosenstock J. et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021; 385: 503-515 DOI: 10.1056/NEJMOA2107519/SUPPL_FILE/NEJMOA2107519_DATA-SHARING.PDF.
• 13 Karagiannis T, Avgerinos I, Liakos A. et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 2022; 65: 1251-1261 DOI: 10.1007/S00125-022-05715-4.
• 14 Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol (Lausanne) 2022; 13: 2570 DOI: 10.3389/FENDO.2022.1004044/BIBTEX.
• 15 Nauck MA, D‘Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 2022; 21: 1-16 DOI: 10.1186/S12933-022-01604-7/TABLES/3.
• 16 Zhang C, Vincelette LK, Reimann F. et al. A brainstem circuit for nausea suppression. Cell Rep 2022; 39 DOI: 10.1016/J.CELREP.2022.110953.
• 17 Frias JP, Bonora E, Ruiz LN. et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care 2021; 44: 765-773 DOI: 10.2337/DC20-1473.
• 18 Van J, Frias JP, Bonora E. et al. Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. Diabetes Ther 2021; 12: 2783-2794 DOI: 10.1007/S13300-021-01140-9.
• 19 Marso SP, Daniels GH, Frandsen KB. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322 DOI: 10.1056/NEJMoa1603827.
• 20 Capehorn MS, Catarig AM, Furberg JK. et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 2020; 46: 100-109 DOI: 10.1016/J.DIABET.2019.101117.
• 21 Rubino DM, Greenway FL, Khalid U. et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022; 327: 138-150 DOI: 10.1001/JAMA.2021.23619.
• 22 Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs 2019; 79: 219-230 DOI: 10.1007/S40265-019-1057-0.
• 23 Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends Endocrinol Metab 2020; 31: 410-421 DOI: 10.1016/J.TEM.2020.02.006.
• 24 Rosenstock J, Blüher M, Schmid B et al. Multiple dose-ranging study of the novel glucagon/GLP-1 receptor dual agonist BI 456906 vs placebo and open-label weekly semaglutide reference control in type 2 diabetes (Abstract number: 613). . Im Internet: https://www.globenewswire.com/news-release/2022/09/21/2520159/0/en/Zealand-Pharma-Announces-Oral-Presentation-of-Phase-2-Data-for-BI-456906-at-the-58th-Annual-Meeting-of-the-European-Associationfor-the-Study-of-Diabetes-EASD.html
• 25 ObesityWeek 2022. Abstract Oral-063. Presented November 3, 2022
• 26 Parker VER, Robertson D, Wang T. et al. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. J Clin Endocrinol Metab 2020; 105 DOI: 10.1210/CLINEM/DGZ047.
• 27 Urva S, Loh MT, Coskun T. et al. 340-OR: LY3437943 (LY), a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment. Diabetes 2022; 71 DOI: 10.2337/DB22-340-OR.
• 28 Griffith DA, Edmonds DJ, Fortin JP. et al. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. J Med Chem 2022; 65: 8208-8226 DOI: 10.1021/ACS.JMEDCHEM.1C01856/SUPPL_FILE/JM1C01856_SI_001.PDF.
• 29 Saxena AR, Gorman DN, Esquejo RM. et al. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med 2021; 27: 1079-1087 DOI: 10.1038/S41591-021-01391-W.
• 30 Pratt E, Ma X, Liu R. et al. Results from a 12-week proof-of-concept study of a novel oral non-peptide GLP-1 receptor agonist in patients with type 2 diabetes. Im Internet: https://www.abstractsonline.com/pp8/#!/10613/presentation/1314
• 31 Mingrone G, Panunzi S, De Gaetano A. et al. Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. N Engl J Med 2012; 366: 1577-1585 DOI: 10.1056/NEJMoa1200111.